Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171260 | 1.00 | HTR6 (0.46) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL15171143 | 0.95 | JAK2 (0.49) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL15711178 | 0.95 | JAK2 (0.49) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL14797959 | 0.93 | JAK1 (0.42) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL31626148 | 0.93 | JAK1 (0.42) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL18645213 | 0.89 | HTR6 (0.47) | HTR6JAK2JAK1HPGDSBTK | |
| SCHEMBL30760777 | 0.88 | JAK2 (0.44) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL30760907 | 0.88 | JAK2 (0.44) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL30760906 | 0.88 | JAK2 (0.44) | HTR6JAK2JAK1SRCEGFR | |
| SCHEMBL30760762 | 0.88 | JAK2 (0.44) | HTR6JAK2JAK1SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | HTR6 1482/4885JAK2 8/4885JAK1 32/4885 |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | HTR6 1482/4885JAK2 8/4885JAK1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.